KalVista Pharmaceuticals ( (KALV) ) has provided an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial position as it prepares for the anticipated U.S. launch of sebetralstat in 2025, potentially revolutionizing HAE treatment with an on-demand oral option.
See more data about KALV stock on TipRanks’ Stock Analysis page.